Information Provided By:
Fly News Breaks for November 10, 2015
ABBV
Nov 10, 2015 | 09:12 EDT
Argus believes that AbbVie's Q3 results show that the company can develop growth drivers other than Humira. The firm thinks that the company is generating strong growth from its new drugs, while its valuation is attractive. Argus keeps a Buy rating on the shares.
News For ABBV From the Last 2 Days
There are no results for your query ABBV